1. Kyoto University Research Information Repository
  2. 060_Graduate School of Medicine
  3. Journal Articles
Downloads: 111

    Please use this identifier to cite or link to this item: http://hdl.handle.net/2433/265297
Files in This Item:
File Description SizeFormat 
jiab368.pdf1.84 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFerreira, Isabellaen
dc.contributor.authorKemp, Stevenen
dc.contributor.authorDatir, Rawlingsen
dc.contributor.authorSaito, Akatsukien
dc.contributor.authorMeng, Boen
dc.contributor.authorRakshit, Parthaen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.authorKosugi, Yusukeen
dc.contributor.authorUriu, Keiyaen
dc.contributor.authorKimura, Izumien
dc.contributor.authorShirakawa, Kotaroen
dc.contributor.authorAbdullahi, Adamen
dc.contributor.authorThe CITIID-NIHR BioResource COVID-19 Collaboration, The Indian SARS-CoV-2 Genomics Consortium (INSACOG)en
dc.contributor.authorAgarwal, Anuragen
dc.contributor.authorOzono, Seiyaen
dc.contributor.authorTokunaga, Kenzoen
dc.contributor.authorGenotype to Phenotype Japan (G2P-Japan) Consortiumen
dc.contributor.authorSato, Keien
dc.contributor.authorGupta, Ravindra K.en
dc.contributor.alternative齊藤, 暁ja
dc.contributor.alternative高折, 晃史ja
dc.contributor.alternative小杉, 優介ja
dc.contributor.alternative瓜生, 慧也ja
dc.contributor.alternative木村, 出海ja
dc.contributor.alternative白川, 康太郎ja
dc.contributor.alternative徳永, 研三ja
dc.contributor.alternative佐藤, 佳ja
dc.date.accessioned2021-09-21T23:32:21Z-
dc.date.available2021-09-21T23:32:21Z-
dc.date.issued2021-09-
dc.identifier.urihttp://hdl.handle.net/2433/265297-
dc.descriptionSARS-CoV-2 B.1.617系統（俗称「インド株」）のL452R変異とE484Q変異は 中和抗体感受性の低下において、相加的な抵抗性を示さない. 京都大学プレスリリース. 2021-08-24.ja
dc.description.abstractThe SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that two key mutations seen in the receptor binding domain L452R and E484Q would have additive effects on evasion of neutralising antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine elicited neutralising antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.en
dc.language.isoeng-
dc.publisherOxford University Press (OUP)en
dc.rights© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.en
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectantibody escapeen
dc.subjectB.1.617en
dc.subjectCOVID-19en
dc.subjectevasionen
dc.subjectfitnessen
dc.subjectIndian varianten
dc.subjectinfectivityen
dc.subjectneutralizing antibodiesen
dc.subjectresistanceen
dc.subjectSARS-CoV-2en
dc.subjectspike mutationen
dc.subjectmutationen
dc.subjectvaccinesen
dc.subjectantibodiesen
dc.subjectpathogenicityen
dc.subjectneutralizing antibodiesen
dc.subjectsars-cov-2en
dc.subjectcovid-19en
dc.subjectcovid-19 vaccinesen
dc.titleSARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasionen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleThe Journal of Infectious Diseasesen
dc.identifier.volume224-
dc.identifier.issue6-
dc.identifier.spage989-
dc.identifier.epage994-
dc.relation.doi10.1093/infdis/jiab368-
dc.textversionpublisher-
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridgeen
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridgeen
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridgeen
dc.addressDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazakien
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridgeen
dc.addressNational Centre for Disease Controlen
dc.addressDepartment of Hematology and Oncology, Kyoto Universityen
dc.addressDivision of Systems Virology, Institute of Medical Science, University of Tokyoen
dc.addressDivision of Systems Virology, Institute of Medical Science, University of Tokyoen
dc.addressDivision of Systems Virology, Institute of Medical Science, University of Tokyoen
dc.addressDepartment of Hematology and Oncology, Kyoto Universityen
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridgeen
dc.addressCSIR Institute of Genomics and Integrative Biologyen
dc.addressDepartment of Pathology, National Institute of Infectious Diseasesen
dc.addressDepartment of Pathology, National Institute of Infectious Diseasesen
dc.addressDivision of Systems Virology, Institute of Medical Science, University of Tokyo; CREST, Japan Science and Technology Agencyen
dc.addressCambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Africa Health Research Instituteen
dc.identifier.pmid34260717-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2021-08-24-
dcterms.accessRightsopen access-
dc.identifier.pissn0022-1899-
dc.identifier.eissn1537-6613-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons